Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the third quarter of 2012, adjusted 2012 GAAP and confirmed non-GAAP EPS guidance.
“Bristol-Myers Squibb faced challenges in the third quarter, including the discontinuation of BMS-986094 for the treatment of hepatitis C. I am proud of how we worked through these challenges and made the right decisions for patients,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We remain strong and well-positioned for future success as demonstrated by the achievement of regulatory milestones for Eliquis and Orencia, the presentation of long-term survival data for Yervoy, the completion of our acquisition of Amylin, and the performance of our key brands.”
|$ amounts in millions, except per share amounts|
|Net Sales||$ 3,736||$ 5,345||(30)%|
|GAAP Diluted EPS||(0.43)||0.56||*|
|Non-GAAP Diluted EPS||0.41||0.61||(33)%|
* In excess of +/- 100%